Teach me about corticosteroids

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Searching PubMed

corticosteroids adverse effects management

The PubMed results are not specifically relevant to a general corticosteroid overview. I now have comprehensive textbook content. Let me compile the full educational response.

Corticosteroids: A Comprehensive Overview

1. What Are Corticosteroids?

Corticosteroids are steroid hormones produced by the adrenal cortex. They fall into two major functional classes:

Class	Primary Hormone	Main Actions
Glucocorticoids	Cortisol	Metabolic, anti-inflammatory, immunosuppressive
Mineralocorticoids	Aldosterone	Salt and water retention, potassium excretion

In addition, the adrenal cortex produces androgens (DHEA, androstenedione) which are weak sex hormone precursors. Both natural and synthetic corticosteroids are used clinically - natural ones for replacement therapy (Addison disease), and synthetic ones - far more commonly - for their anti-inflammatory and immunosuppressive properties.

2. Biosynthesis and Regulation

Adrenocortical steroids are synthesized from cholesterol via a series of enzymatic steps:

Cholesterol → Pregnenolone (rate-limiting step, stimulated by ACTH)
Pregnenolone → Progesterone → Cortisol (via 17α-hydroxylation)
Pregnenolone → Corticosterone → Aldosterone (via a separate pathway)

Regulation:

Glucocorticoid secretion is controlled by the HPA axis: hypothalamus releases CRH → pituitary releases ACTH → adrenal cortex releases cortisol. Cortisol then feeds back negatively on both hypothalamus and pituitary.
Mineralocorticoid (aldosterone) secretion is primarily regulated by the renin-angiotensin system and serum potassium, not ACTH.
Katzung's Basic and Clinical Pharmacology, 16th Ed., p. 1103

3. Mechanism of Action

Genomic (Slow) Pathway - Primary Mechanism

Corticosteroid diffuses into the cell and binds to cytoplasmic glucocorticoid receptors (GRs), which are held inactive by heat shock proteins (HSPs).
Binding dissociates the HSP-GR complex, activating the receptor.
The active GR complex translocates to the nucleus, dimerizes, and binds glucocorticoid response elements (GREs) on DNA.
This induces or suppresses gene transcription - e.g., suppressing cytokine genes (IL-1, IL-2, TNF-α) and inducing lipocortin (annexin-1).

Non-Genomic (Rapid) Pathway

Rapid effects (seconds to minutes) - such as initial ACTH suppression - occur too quickly to be explained by transcription. These likely involve direct membrane receptor interactions or G-protein-coupled pathways. All steroid receptors except mineralocorticoid receptors have palmitoylation motifs enabling plasma membrane localization.

Key Downstream Effects

NF-κB inhibition: Corticosteroids stimulate IκB, which sequesters NF-κB (a master pro-inflammatory transcription factor), limiting cytokine gene expression.
Phospholipase A2 inhibition: Via lipocortin/annexin-1 induction → blocks arachidonic acid release → reduces both prostaglandins and leukotrienes.
AP-1 inhibition: Attenuates another major inflammatory transcription factor.
Neutrophil effects: Cause neutrophilia (demargination) but inhibit neutrophil chemotaxis and adhesion to endothelium.
Comprehensive Clinical Nephrology, 7th Ed., p. block14; Katzung's, p. 1105-1107

4. Physiologic Effects of Glucocorticoids

Metabolic Effects (Dose-Dependent)

System	Effect
Carbohydrate	↑ Gluconeogenesis, ↑ glycogen synthesis, ↑ serum glucose, ↓ peripheral glucose uptake
Protein	Catabolism in muscle, lymphoid tissue, skin, bone (anabolic in liver)
Fat	↑ Lipolysis + ↑ lipogenesis → net fat redistribution (central obesity, moon face, buffalo hump)
Bone	Anti-anabolic → osteoporosis; ↓ growth in children

"Permissive Effects"

At physiologic levels, glucocorticoids are required for normal vascular and bronchial smooth muscle responses to catecholamines - without them, vasopressor response is blunted (relevant in adrenal crisis).

Cardiovascular

Maintain vascular tone and cardiac output
Excess → hypertension (via mineralocorticoid-like sodium retention and increased vascular reactivity)

Immune/Inflammatory

Redistribute lymphocytes from circulation to lymphoid tissue (lymphopenia)
Suppress virtually all phases of inflammation

5. Pharmacokinetics

Parameter	Detail
Bioavailability	Oral prednisone/prednisolone: good oral bioavailability
Plasma half-life	60-180 minutes
Biologic half-life	18-36 hours (much longer than plasma half-life)
Metabolism	Hepatic conjugation, renal excretion as inactive metabolites
Drug interactions	CYP3A4 inducers (rifampin, phenytoin) → ↓ levels; CYP3A4 inhibitors (ketoconazole) → ↑ levels

Comprehensive Clinical Nephrology, 7th Ed.

6. Classification and Relative Potency

Synthetic glucocorticoids are designed to maximize anti-inflammatory potency while minimizing mineralocorticoid activity:

Drug	Glucocorticoid Potency	Mineralocorticoid Potency	Duration
Cortisol (hydrocortisone)	1 (reference)	1	Short (8-12h)
Prednisone	4	0.8	Intermediate
Methylprednisolone	5	0.5	Intermediate
Dexamethasone	25-30	~0	Long (36-54h)
Fludrocortisone	10	125	(used as mineralocorticoid)
Betamethasone	25-30	~0	Long

Key principle: Longer-acting agents (dexamethasone) cause greater HPA axis suppression.

7. Clinical Uses

Corticosteroids are among the most widely used drugs in medicine, with applications across virtually every specialty:

Replacement Therapy

Adrenal insufficiency (Addison disease, secondary adrenal insufficiency)
Congenital adrenal hyperplasia

Anti-inflammatory / Immunosuppressive Uses

Rheumatologic: Rheumatoid arthritis, SLE, vasculitis, polymyalgia rheumatica
Pulmonary: Asthma (inhaled and systemic), COPD exacerbations, interstitial lung disease, sarcoidosis
Dermatologic: Atopic dermatitis, psoriasis, contact dermatitis (topical and systemic)
Renal: Nephrotic syndrome, glomerulonephritis, transplant immunosuppression
GI: Inflammatory bowel disease (Crohn's, ulcerative colitis)
Hematologic: Immune thrombocytopenia (ITP), autoimmune hemolytic anemia
Neurologic: Brain edema (dexamethasone), multiple sclerosis exacerbations, meningitis
Oncology: Lymphoma, leukemia, anti-emesis with chemotherapy, hypercalcemia of malignancy
Septic shock: Relative adrenal insufficiency (low-dose hydrocortisone)
Organ transplantation: Prevention and treatment of rejection

In RA, corticosteroids are used chronically in 30-70% of patients; effects are prompt and dramatic but the goal is always to use the lowest effective dose.

Katzung's, Chapter 39

8. Adverse Effects

This is the most clinically important area - the "price" of prolonged corticosteroid therapy.

Major Adverse Effects by System

System	Effect
Metabolic	Hyperglycemia / steroid diabetes, hyperlipidemia, weight gain, central obesity
Musculoskeletal	Osteoporosis, avascular necrosis (esp. femoral head), proximal myopathy
Ophthalmologic	Posterior subcapsular cataracts, glaucoma
Cardiovascular	Hypertension, fluid retention
Dermatologic	Skin thinning/striae, easy bruising, acne, impaired wound healing
Endocrine	HPA axis suppression → adrenal insufficiency on withdrawal; Cushingoid features
Psychiatric	Mood changes, euphoria, depression, psychosis, insomnia
GI	Peptic ulcer disease (especially with NSAIDs), pancreatitis, colonic perforation
Immune	Increased infection susceptibility (bacterial, fungal, viral, opportunistic)
Growth	Retardation in children

Infection risk is particularly high with prolonged high-dose therapy. Notably, 86% of patients with large-vessel vasculitis experience glucocorticoid-related adverse events at 10-year follow-up. - Braunwald's Heart Disease

HPA Axis Suppression (Steroid Withdrawal)

Prolonged supraphysiologic dosing suppresses ACTH production. Abrupt discontinuation can cause adrenal crisis (nausea, vomiting, hypotension, shock). Tapering is required for courses >3 weeks.

Prevention Strategies

Use the lowest effective dose for the shortest time
Use inhaled rather than systemic when possible (asthma)
Alternate-day dosing reduces HPA suppression
Calcium + Vitamin D supplementation for bone protection
Consider bisphosphonates for osteoporosis prevention in long-term use
PPI co-prescription when combined with NSAIDs

9. Topical Corticosteroids (Dermatology)

Topical corticosteroids are classified into 7 potency classes (Class I = super-potent, Class VII = low potency). Key points:

Under normal conditions, ~99% of applied topical corticosteroid is cleared from skin; only ~1% is therapeutically active.
Local side effects include skin atrophy, striae, telangiectasia, and perioral dermatitis.
Systemic absorption can occur with high-potency agents on large surface areas (especially in children).
Fitzpatrick's Dermatology, Volumes 1 & 2

10. Mineralocorticoids

Fludrocortisone is the only clinically used mineralocorticoid. It acts on renal distal tubule collecting ducts to:

Increase sodium reabsorption
Increase potassium excretion
Retain water

Uses: Addison disease replacement (with hydrocortisone), orthostatic hypotension, salt-wasting forms of congenital adrenal hyperplasia.

Quick Memory Aid

Glucocorticoids: "BECLOMETHASONE" effects
B - Blood sugar ↑
E - Edema (Na/water retention)
C - Cushing's features
L - Lymphopenia
O - Osteoporosis
M - Mood changes
E - Eyes (cataracts)
T - Thinning skin
H - Hypertension
A - Adrenal suppression
S - Susceptibility to infection
O - Obesity (central)
N - Nitrogen catabolism (muscle wasting)
E - Elevation of lipids

Summary

Corticosteroids are powerfully effective drugs for a vast range of inflammatory and immune conditions, but their use carries a significant burden of metabolic, endocrine, musculoskeletal, and infectious adverse effects. The therapeutic goal is always to use the minimum effective dose for the shortest necessary duration, with appropriate preventive measures when long-term use is unavoidable.

Sources: Katzung's Basic and Clinical Pharmacology 16th Ed., Chapter 39; Comprehensive Clinical Nephrology 7th Ed.; Fitzpatrick's Dermatology; Braunwald's Heart Disease

This is a shared conversation. Sign in to Orris to start your own chat.